Publication | Closed Access

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

UrologyCisplatin Plus GemcitabineGastrointestinal OncologyMedicineBiliary CancerMolecular OncologyCancer TreatmentOncologyRadiation OncologyCancer ResearchJapanese Patients